The medical technology firm reaffirms Q2 2026 EPS guidance of $2.95-$3.05 after stronger-than-expected 12.5% sales growth.
Edwards Lifesciences increased its 2026 sales growth outlook to 10%-11%, up from a prior range, while maintaining its Q2 2026 earnings per share guidance of $2.95-$3.05. The revision follows a 12.5% sales increase in the second quarter, exceeding internal expectations.
The company attributed the performance to broad strength across therapies and geographies. Prior quarter growth had been reported at a lower rate, with consensus estimates aligning closer to the revised outlook. The guidance reaffirmation suggests confidence in sustained momentum.
No immediate market reaction was detailed in the earnings call summary.